Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 19, 2025
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 19, 2025
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of …
JOP Partners with Strategy Deployment Limited to Help Businesses Achieve Their Goals More Effectively
EIN Presswire
·
March 19, 2025
JOP partners with SDL to expand in the UK, bringing its OKR and CPM solutions to businesses with localized support for seamless adoption and growth. DELHI, NEW DELHI, INDIA, March 19, 2025 /EINPresswire.com/ -- JOP (Joy of Performing), a leading …
Galecto Reports Full-Year 2024 Financial Results
GlobeNewswire
·
March 19, 2025
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines GB3226 on track for IND …
UbiVac to present on Dark Genome-derived Dark Matter/Proteome Cancer Immunotherapy at Spring 2025 Venture Forum
EIN Presswire
·
March 19, 2025
UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Clinic - Promising Early Data Supports Phase II Trial PORTLAND, OR, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- UbiVac, www.ubivac.com, a private, clinical-stage Immuno- …
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
GlobeNewswire
·
March 19, 2025
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received …
Basel Medical Group Ltd Announces Exercise of Overallotment Option
GlobeNewswire
·
March 19, 2025
Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as …
A' Mindfulness and Meditation Products Design Award Announces Comprehensive Prize Package for 2024
EIN Presswire
·
March 19, 2025
A' Design Award Unveils Extensive Benefits Package for Winners of the 2024 Mindfulness and Meditation Products Design Competition COMO, CO, ITALY, March 19, 2025 /EINPresswire.com/ -- The A' Mindfulness and Meditation Products Design Award, a highly …
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
GlobeNewswire
·
March 19, 2025
– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q …
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 19, 2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth …
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 19, 2025
Announced the U.S. FDA has accepted our Biologics License Application (BLA) seeking full approval of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy BLA granted priority review with a Prescription Drug User Fee Act (PDUFA) …
TILT Holdings Reports Fourth Quarter and Full Year 2024 Results
GlobeNewswire
·
March 19, 2025
PHOENIX, March 19, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (Cboe CA: TILT) (OTCQB: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand …
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
GlobeNewswire
·
March 19, 2025
SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug …
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 19, 2025
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the …
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewswire
·
March 19, 2025
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and …
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 19, 2025
Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical focus for CNTY-101 based on unique …
iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024
GlobeNewswire
·
March 19, 2025
NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported …
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
GlobeNewswire
·
March 19, 2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has …
Akebia Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire
·
March 19, 2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an …
Horses.vn Brings the Joy of Horseback Riding to Central Vietnam
EIN Presswire
·
March 19, 2025
DA NANG, HOI AN, VIETNAM, March 19, 2025 /EINPresswire.com/ -- Horses.vn Brings the Joy of Horseback Riding to Central Vietnam Central Vietnam is about to experience a new level of excitement as Horses.vn, founded by Hongly Nguyen and her husband …
AI STARTUP REENA.AI ANNOUNCES FILING OF PATENT FOR REVOLUTIONARY COLLABORATION TECHNOLOGY FOR THE DENTAL INDUSTRY
EIN Presswire
·
March 19, 2025
SCOTTSDALE, AZ, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- Innovative startup reena.ai has filed a patent for its groundbreaking AI-powered communication system designed for the global dental and healthcare industries. The technology, named " …